Issue link: https://viewer.e-digitaledition.com/i/449285
performed at separate times. We are also able, at the time of surgery, to resect the left atrial appendage, which research suggests accounts for up to 80 percent of strokes caused by AF." Assisting the Heart According to the American Heart Association, approximately 5.1 million Americans have heart failure. Half of this population dies within five years of diagnosis. When medications prove ineffective, the best curative option is transplant, but that isn't always possible. Many transplant candidates require intervention before a transplant can be performed, and because demand exceeds supply, many die wait- ing for a transplant. Other patients are too old and frail to undergo major heart surgery. Traditionally, the only options for this patient population were hospice and palliative care. St. Luke's physicians offer these patients an additional alternative — the HeartMate II Left Ventricular Assist System. Traditional LVADs mimic the pulsatile pumping of the heart, creating variable diastolic and systolic blood pres- sure. The HeartMate II, however, uses a centrifugal pump mechanism — similar to submarine propellers — to maintain con- stant cardiac output, which makes it more durable and less prone to complications. The device was initially used as a bridge to transplant, implanted to assist patients whose hearts could not function on their own when a transplant wasn't available. But now, the device's efficacy has brought it to broader use as a destination or permanent therapy. When medications don't treat end-stage heart fail- ure causing symptoms at rest, David Allen, DO, cardiologist at St. Luke's, evaluates patients for potential treatment using the HeartMate II. "The HeartMate II has revolutionized treatment for these patients," Dr. Durkin says. "Nationally, there are not enough donor hearts to come any where near the number needed to treat all the potentially eligible patients. Having the option to use the HeartMate II as a bridge to transplant or as a permanent therapy offers people with end-stage heart failure more opportunities for a prolonged and better life." Transforming Smartphones into Portable ECGs Dr. Traub provides the full spectrum of treatments for heart rhythm disorders. To help patients stay out of the hospital, monitor known rhythm disturbances and even make new diagnoses in patients with rhythm disturbances that occur at infrequent intervals, he uses the AliveCor Heart Monitor. The small device integrates with a smartphone application — the AliveECG app — to record electrocar- diograms whenever patients experience arrhythmic symptoms, such as lightheaded- ness or palpitations. Traditional monitoring devices are larger, require patients to wear leads on their chests and are only available for up to one month of monitoring at a time. Long-term monitors (up to three years), though now miniatur- ized, require surgical implantation, and AliveCor Heart Monitor Stephen A. Olenchock, DO, and Raymond A. Durkin, MD many patients don't want to undergo an invasive procedure if their conditions can be otherwise managed. "For approximately two years, I have used this for a number of my patients who experience symptoms from heart rhythm disturbances every few months or who have AF with difficult-to-control heart rates," Dr. Traub says. "The AliveCor Heart Monitor is an excellent option for those who don't want surgically implanted devices. Specially designed smartphone cases fea- ture a compartment for the heart monitor. When experiencing symptoms from heart rhythm disturbances, patients place their fingers on the device, record the heart rhythm and email the electrocardiogram to me." This device permits Dr. Traub to iden- tify and medically manage arrhythmias remotely, allowing patients to maintain their usual schedules until they can arrange an office visit. The monitor even allows remote management of patients with tachycardia- bradycardia syndrome, a particularly challenging condition. When in AF, their heart rate is too fast and their normal sinus rhythm is often too slow, according to Dr. Traub. Medicinal regimens must account for these irregularities and still maintain normal rhythms. Sapien XT TAVR valve M D N E W S . CO M ■ MD NEWS Eastern Pennsylvania/NW New Jersey | 1 1

